Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.

OBJECTIVES This study was conducted to generate basic pharmacodynamic information on the relationship between antibiotic concentrations and the growth of rapidly growing mycobacteria (RGM), and thereby contribute to a better understanding of current and future drug regimens for diseases caused by RGM. METHODS Type strains of Mycobacterium abscessus and Mycobacterium fortuitum were used; the MICs of cefoxitin, amikacin, moxifloxacin, linezolid and clarithromycin were determined by broth microdilution. Time-kill assays were performed, exposing the bacteria to 2-fold concentrations from 0.25 to 32 times the MIC at 30°C for 120 h. The sigmoid maximum effect (Emax) model was fitted to the time-kill curves data. RESULTS The highest killing of M. abscessus was observed between 24 and 72 h; amikacin had the highest Emax (0.0427 h(-1)), followed by clarithromycin (0.0231 h(-1)) and cefoxitin (0.0142 h(-1)). For M. fortuitum, between 3 and 24 h, amikacin also showed the highest Emax (0.1933 h(-1)). There were no significant differences between the Hill's slopes determined for all the antibiotics tested against M. abscessus or M. fortuitum (P = 0.2213 and P = 0.2696, respectively). CONCLUSIONS The total effect observed for all antibiotics was low and primarily determined by the Emax and not by the Hill's slope. The limited activity detected fits well with the poor outcome of antibiotic treatment for disease caused by RGM, particularly for M. abscessus. An evaluation of drug combinations will be the next step in understanding and improving current treatment standards.

[1]  D. van Soolingen,et al.  Antimycobacterial Agents Differ with Respect to Their Bacteriostatic versus Bactericidal Activities in Relation to Time of Exposure, Mycobacterial Growth Phase, and Their Use in Combination , 2005, Antimicrobial Agents and Chemotherapy.

[2]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[3]  A. van Belkum,et al.  Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. , 2010, The Journal of antimicrobial chemotherapy.

[4]  F. Drobniewski,et al.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study , 2013, European Respiratory Journal.

[5]  J. Gaillard,et al.  In vivo evaluation of antibiotic activity against Mycobacterium abscessus. , 2014, The Journal of infectious diseases.

[6]  D. van Soolingen,et al.  Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence , 2013, Expert review of anti-infective therapy.

[7]  S. Shin,et al.  Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[8]  B. Markova,et al.  Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin , 1994, Antimicrobial Agents and Chemotherapy.

[9]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. , 2002, International journal of antimicrobial agents.

[10]  O. Cars,et al.  Tissue concentrations: do we ever learn? , 2007, The Journal of antimicrobial chemotherapy.

[11]  G. Bloemberg,et al.  Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus , 2014, Antimicrobial Agents and Chemotherapy.

[12]  J. Zuckerman,et al.  Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). , 2011, The Medical clinics of North America.

[13]  C. Daley,et al.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.

[14]  J. Alffenaar,et al.  Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. , 2013, International journal of antimicrobial agents.

[15]  K. Greenwood-Quaintance,et al.  Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[16]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .